Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XBN
|
|||
| Former ID |
DIB009621
|
|||
| Drug Name |
ACT-GRO-777
|
|||
| Synonyms |
AGRO-100; AS-1411; Anticancer aptamers, Aptamera; GRO-26B; AGRO-100 derivatives, Aptamera; Nucleolin inhibitors (cancer), Aptamera; Nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Aptamer
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Aptamera Inc
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nucleolin (NCL) | Target Info | . | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Aurora B signaling | |||
| Validated targets of C-MYC transcriptional activation | ||||
| Regulation of Telomerase | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| WikiPathways | Pathogenic Escherichia coli infection | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00740441) A Phase II Study of AS1411 in Renal Cell Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.